Retinal toxicity screening underused for hydroxychloroquine therapy│ EULAR
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
There were significant deficiencies in guideline-based screening in Irish patients treated with hydroxychloroquine (HCQ) for connective tissue disease, with a high level of toxicity shown in patients who did undergo screening.
Why this matters
HCQ-related visual toxicity is usually permanent with possible progression up to years after drug cessation and with no current treatment available.
Early detection is essential for preserving central vision and foveal architecture.
Investigators examined the medical records of 161 patients with connective tissue disease treated at a regional rheumatology center in order to determine compliance with the American Academy of Ophthalmology Recommendation on Screening for Chloroqui...